TICKERNERD
Menu
BIOBIOHealthcare · Medical Devices

BIO Stock Forecast: Bio-Rad Laboratories, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$376
−1.57% on the day

The 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. hold a median 12-month price target of $330 — -12.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 19 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$10.1B
Ticker Nerd rank
90 / 100
Median analyst target
$330
Analysts covering
5
Revenue$651.0M−0.1% y/y
Operating income$72.6M
Net income$371.4M
Free cash flow$66.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.9%
1M
+6.7%
YTD
+24.2%
1Y
+31.4%
From 52W high
−3.6%
From 52W low
+55.7%
$242
$390
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bio-Rad Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
92
Issuance
88
Volatility
85
Revisions
79
Momentum
78
Quality
70
Accruals
65
Growth
44
Size
15

Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (44): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Oct 25Jan 26Apr 26Jul 26BIOHigh $390Median $330Low $280

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
1 Buy3 Hold1 Sell
Low $280Median $330High $390

The green dot is the last close — the median target sits −12.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsOutperform$370 → $390
5 Aug 2026CitigroupMaintainsNeutral$300 → $330
5 Aug 2026RBC CapitalMaintainsOutperform$320 → $370
5 Aug 2026Wells FargoMaintainsEqual-Weight$310 → $330
15 May 2026RBC CapitalReinstatesOutperform$320
1 May 2026Wells FargoMaintainsEqual-Weight—
7 Apr 2026CitigroupDowngradeNeutral—
16 Feb 2026Wells FargoMaintainsEqual-Weight—
30 Oct 2025CitigroupMaintainsBuy—
30 Oct 2025Wells FargoMaintainsEqual-Weight—
1 Aug 2025RBC CapitalMaintainsOutperform—
1 Aug 2025Wells FargoMaintainsEqual-Weight—
9 June 2025Wells FargoMaintainsEqual-Weight—
2 May 2025CitigroupMaintainsBuy—
2 May 2025RBC CapitalMaintainsOutperform—
2 May 2025UBSMaintainsBuy—
17 Apr 2025Wells FargoMaintainsEqual-Weight—
12 Feb 2025Wells FargoMaintainsEqual-Weight—
14 Jan 2025RBC CapitalReiteratesOutperform—
9 Dec 2024RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Bio-Rad Laboratories, Inc. returned +31.4% against +16.3% for the S&P 500, dividends included.

BIO vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Oct 25Jan 26Apr 26Jul 26BIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.3%
Analysts raising
4
Analysts cutting
0
Fundamentals

Bio-Rad Laboratories, Inc. (BIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
45.8×

Cheaper than 16% of US stocks

Price / sales
3.9×

Cheaper than 31% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
22.3×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
−0.1%

Higher than 27% of US stocks

Earnings growth (YoY)
16.9%

Higher than 55% of US stocks

Gross margin
53.1%

Higher than 66% of US stocks

Operating margin
11.2%

Higher than 66% of US stocks

Net margin
8.6%

Higher than 67% of US stocks

Returns & dividend
Return on equity
3.1%

Higher than 50% of US stocks

Return on assets
1.7%

Higher than 56% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bio-Rad Laboratories, Inc. (BIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bio-Rad Laboratories, Inc. has a market value of $10.1B and an enterprise value of $9.8B.

  • Revenue in the twelve months to 30 June 2026: $2.6B. The latest quarter shrank 0.1% year on year.

  • Net income over the same four quarters: $222.4M, a 8.6% net margin.

  • Diluted earnings per share, trailing twelve months: $8.25.

  • Free cash flow in the twelve months to 30 June 2026: $353.1M.

  • Bio-Rad Laboratories, Inc. spent $132.7M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 26.7M.

  • Trailing P/E: 45.8×; forward P/E: 37.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Bio-Rad Laboratories, Inc. employs 7,450 people — $348K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

BIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BIOBio-Rad Laboratories, Inc.$10.1B
90
TXG10X Genomics, Inc.$10.0B
94
GMEDGlobus Medical, Inc.$9.9B
96
PODDInsulet Corp.$9.7B
89
GKOSGlaukos Corp.$9.7B
92
BRKRBruker Corp.$9.3B
87
PENPenumbra, Inc.$12.5B
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bio-Rad Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIO news & analysis

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

Business Wire · 16 Sept 2026neutral

Bio-Rad Laboratories announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on September 24, 2026, at 8:50 AM Eastern Time. A live webcast and replay of the event will be available in the Investor Relations section.

Why it matters — A Bio-Rad watcher would care because the CFO's participation at a major investor forum offers an opportunity to hear the company's leadership discuss its business directly with the investment community.

Bio-Rad: Favorable Read-Across From Investor Event

Seeking Alpha · 10 Sept 2026positive

Bio-Rad Laboratories management, speaking at the Wells Fargo Healthcare conference, laid out long-term operating margin targets of 20% with intermediate milestones in the mid-teens. Margin drivers cited include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.

Why it matters — These margin targets exceed consensus expectations, giving BIO watchers a favorable read on the company's longer-term profitability outlook.

Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

Bio-Rad Laboratories, Inc. presented at the Wells Fargo 21st Annual Healthcare Conference, and a transcript of that presentation was published on Seeking Alpha. The item reports on the company's conference participation.

Why it matters — A BIO watcher would care because a transcript of the company's presentation at a major industry conference can offer insight into its strategic positioning and outlook.

Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 3 Sept 2026positive

Bio-Rad (BIO) reported earnings 30 days ago, and its stock has risen 11.7% since that report. The article examines whether the shares can sustain this upward momentum going forward.

Why it matters — A Bio-Rad watcher would care because the piece assesses whether the stock's post-earnings gains are likely to persist, a key signal for investors following the company.

Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference

Business Wire · 31 Aug 2026neutral

Bio-Rad Laboratories announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat during Wells Fargo's 21st Annual Healthcare Conference on September 9, 2026, at 3:45 PM Eastern Time. A live webcast and replay of the event will be available in the Investor Relations section.

Why it matters — Bio-Rad watchers would be interested because the CFO's appearance at a major healthcare conference offers an opportunity for investors to hear directly about the company's outlook and strategy.

FAQ

Frequently asked questions about BIO stock

What is the BIO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. have a median 12-month price target of $330, with estimates ranging from $280 to $390. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIO stock a buy right now?

Of the 5 analysts covering Bio-Rad Laboratories, Inc., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bio-Rad Laboratories, Inc. 90 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIO?

As at 19 Sept 2026, Bio-Rad Laboratories, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).

Will BIO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -12.3% from the last close, and Ticker Nerd's factor model ranks Bio-Rad Laboratories, Inc. 90 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIO stock forecast for 2030?

No analyst covering Bio-Rad Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $390 over the next 12 months.

How has BIO stock performed over the past year?

Bio-Rad Laboratories, Inc. returned +31.4% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bio-Rad Laboratories, Inc. do?

Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing.

What is the latest news on BIO?

The most recent item we track (Business Wire, 16 Sept 2026): "Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum". Bio-Rad Laboratories announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on September 24, 2026, at 8:50 AM Eastern Time. A live webcast and replay of the event will be available in the Investor Relations section.

Company

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing. Bio-Rad Laboratories Inc. serves two main business segments: Life Science and Clinical Diagnostics. Its Life Science portfolio includes instruments, reagents, consumables, software, and content used to separate, purify, identify, and analyze biological materials such as cells, proteins, and nucleic acids. Its Clinical Diagnostics offerings include test systems, test kits, informatics tools, and quality controls used in areas such as diabetes monitoring, blood typing, infectious disease testing, autoimmune disorders, and genetic analysis. The company’s products are used by universities, hospitals, public health organizations, commercial laboratories, biotechnology firms, pharmaceutical companies, and food and environmental testing customers. Headquartered in Hercules, California, Bio-Rad Laboratories Inc. is recognized as a global supplier of tools that support scientific discovery and diagnostic decision-making.

CEO Mr. Norman D. Schwartz · 7,450 employees · United States · https://www.bio-rad.com